ExLibris header image
SFX Logo
Title: Development and Characterization of a Wee1 Kinase Degrader
Source:

Cell Chemical Biology [2451-9456] Li, Zhengnian yr:2020


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Blanco, M. "New Chemical Modalities and Strategic Thinking in Early Drug Discovery." ACS Medicinal Chemistry Letters 11.3 (2020): 228-231. Link to Full Text for this item Link to SFX for this item
2. Xue, G. "Protein degradation through covalent inhibitor-based PROTACs." Chemical communications (1996) 56.10 (2020): 1521-1524. Link to SFX for this item
3. Duerr, C. "Antibody-drug conjugates- stability and formulation." European journal of pharmaceutics and biopharmaceutics. 139: 168-176. Link to SFX for this item
4. Lipinski, Christopher A. "Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions." Advanced drug delivery reviews 101.C (2016): 34-41. Link to SFX for this item
5. LIPINSKI, Christopher A. "Lead- and drug-like compounds: the rule-of-five revolution." Drug discovery today. Technologies 1.4 (2004): 337-341. Link to SFX for this item
6. Bargh, Jonathan D. "Cleavable linkers in antibody–drug conjugates." Chemical Society reviews. 48.16: 4361-4374. Link to SFX for this item
7. Liu, Q. "Developing Irreversible Inhibitors of the Protein Kinase Cysteinome." Chemistry & biology 20.2 (2013): 146-159. Link to SFX for this item
8. Lipinski, C A A. "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings." Advanced drug delivery reviews 23.1 (2001): 3-26. Link to Full Text for this item Link to SFX for this item
9. Dalton, Samuel E. "Covalent Small Molecules as Enabling Platforms for Drug Discovery." Chembiochem. 21.8: 1080-1100. Link to SFX for this item
10. Zeng, M. "Exploring Targeted Degradation Strategy for Oncogenic KRASG12C." Cell Chemical Biology 27.1: 19-. Link to SFX for this item
11. Zhou, Z. "Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases." Trends in molecular medicine 25.12 (2019): 1094-1109. Link to SFX for this item
12. Ma, D. "A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer." Theranostics 10.8 (2020): 3708-3721. Link to Full Text for this item Link to SFX for this item
13. Guan, H. "Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system." Drug development and industrial pharmacy 43.4 (2017): 519-530. Link to SFX for this item
14. Twyman, Lance J. "The synthesis of water soluble dendrimers, and their application as possible drug delivery systems." Tetrahedron Letters 40.9 (1999): 1743-1746. Link to Full Text for this item Link to SFX for this item
15. Andrews, C.W. W. "Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship." Pharmaceutical research 17.6 (2000): 639-644. Link to Full Text for this item Link to SFX for this item
16. Pardridge, W M M. "CNS drug design based on principles of blood-brain barrier transport." Journal of neurochemistry 70.5 (1998): 1781-92. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.